and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The press release is furnished as Exhibit 99.1 to this repo…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The press release is furnished as Exhibit 99.1 to this repo…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The press release is furnished as Exhibit 99.1 to this repo…

Entry into a Material Definitive Agreement. Underwritten Registered Offering On September 23, 2025, Monopar Therapeutics Inc., a Delaware corporation (the “ Company ” or “ Monopar ”), entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Barclays Capital Inc. (collectively, the “ Representatives ”), as Representatives of the several underwriters named therein (together with the Representatives, the “ Underwriters ”), pu…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Chief Financial Officer — Karthik Radhakrishnan: Mr. Karthik Radhakrishnan's employment terminated, and Quan Vu was appointed as the new Chief Financial Officer.

Director — Michael J. Brown: Michael J. Brown resigned from the Board of Directors.

Unregistered Sales of Equity Securities The information in

Entry into a Material Definitive Agreement. Underwritten Registered Offering On December 20, 2024, Monopar Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co. (the “ Representative ”) as Representative of the several underwriters named therein (together with the Representative, the “ Underwriters ”), pursuant to which the Company will issue and sell to the Underwriters pursuant to the Und…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Entry into a Material Definitive Agreement. On October 28, 2024, Monopar Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a placement agent agreement (the “ Placement Agent Agreement ”) with Rodman & Renshaw LLC (the “ Placement Agent ”) in connection with the offer and sale to investors of up to 1,181,540 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share, at an offering price of $16.25 per Share (the “ Offering ”). In connection with t…

Creation of a Direct Financial Obligation. The information set forth in

Completion of Acquisition or Disposition of Assets. The information set forth in

The Shares are being sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering.

Entry into a Material Definitive Agreement. On October 23, 2024, Monopar Therapeutics Inc. (the “Company” or “Monopar”) executed a License Agreement effective October 23, 2024 (the “License Agreement”) with Alexion Pharmaceuticals, Inc. (“Alexion, AstraZeneca Rare Disease” or “Alexion”), pursuant to which Alexion, AstraZeneca Rare Disease granted the Company an exclusive worldwide license for the development and commercialization of ALXN-1840, a drug candidate for Wilson disease that has prog…

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Material Modification to Rights of Security Holders. The information under

Regulation FD Disclosure. On June 11, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing an amendment and expansion to their existing collaboration with NorthStar Medical Radioisotopes, LLC. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Chief Financial Officer — Kim R. Tsuchimoto: Ms. Tsuchimoto is retiring from her role as CFO, but will continue to serve on the Board of Directors.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.